RSS   Newsletter   Contact   Advertise with us
Post Online Media

Inspyr names Christopher Lowe president and CEO

InspyrInspyr Therapeutics, Inc., a clinical-stage biotechnology company, appoints Christopher Lowe as president and CEO, and as a member of the company’s board of directors.

Mr. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Company’s Board of Directors since March 2016.

Mr. Lowe is an accomplished C-level financial and operational executive. He previously was interim CEO and CFO of publicly traded medical technology company Hansen Medical, and CFO and Chief Business Officer of publicly traded drug development company Anthera Pharmaceuticals.

Prior to that, Mr. Lowe served in various senior financial positions that included CFO of Asthmatx, a medical device company acquired by Boston Scientific, and Chief Accounting Officer and Corporate Controller of Peninsula Pharmaceuticals acquired by Johnson & Johnson.

Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an MBA from Saint Mary’s University, Texas. He serves on the Board of Directors of privately held EpiBiome.


 LATEST MOVES FROM Texas 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy